KANCERA
KANCERA
Social Links:
Industry:
Biotechnology Health Care
Founded:
2010-01-01
Address:
Solna, Stockholms Lan, Sweden
Country:
Sweden
Website Url:
http://www.kancera.com
Total Employee:
1+
Status:
Active
Technology used in webpage:
Viewport Meta IPhone / Mobile Compatible SPF SSL By Default Google Font API LetsEncrypt Apple Mobile Web Clips Icon WordPress Content Delivery Network Google Universal Analytics
Similar Organizations
Beta Innov
Pharmaceutical Research and Development
Oncoscience
Oncoscience is a biopharmaceutical company
Current Employees Featured
Official Site Inspections
http://www.kancera.com Semrush global rank: 4.88 M Semrush visits lastest month: 1.8 K
- Host name: webfront6.webcluster.loopia.se
- IP address: 93.188.2.56
- Location: Sweden
- Latitude: 59.3247
- Longitude: 18.056
- Timezone: Europe/Stockholm
More informations about "kancera"
Kancera » About Us
Kancera’s management team has extensive expertise and experience of translating medical discovery into candidate drugs and developing these into marketed products in partnership …See details»
Kancera
Delårsrapport för tredje kvartalet 2024, 1 juli – 30 september Kancera AB (publ.), org.nr. 556806-8851 2024-11-12 Kancera fokuserar på kardiovaskulära sjukdomarSee details»
Kancera
Kancera develops pharmaceuticals for life threatening diseases with high medical needs. Read More. Our science. Kancera develops a new class of drugs targeting the fractalkine axis. Read …See details»
kancera - Crunchbase Company Profile & Funding
TradingView — Kancera Q1 Operating Loss Narrows To SEK 13.4 Mln News • May 3, 2024 TradingView — Kancera meets the primary objectives of the KAND145 clinical phase I studySee details»
Kancera - LinkedIn
Kancera | 3,438 followers on LinkedIn. Kancera is developing a new class of drugs for treatment of inflammation and cancer | Kancera is a Swedish based biotechnology company that is …See details»
Kancera Information - RocketReach
Kancera is a Swedish based biotechnology company that is developing a new class of small molecule drugs based on the fractalkine system. Fractalkine is a master regulator that controls …See details»
Kancera AB - Nordic Issuing
Oct 28, 2022 1 Nov - 15 Nov 2022 Rights issue. Kancera is a world leader in developing small molecule drugs for cancer and inflammation. The company’s two main drug candidates are …See details»
Kancera AB - Drug pipelines, Patents, Clinical trials - Synapse
Explore Kancera AB with its drug pipeline, therapeutic area, technology platform, 7 clinical trials, 2 news, Disease Domain:Neoplasms, Endocrinology and Metabolic Disease, Immune System …See details»
Kancera - VentureRadar
Kancera develops the basis for new therapeutics, starting with new treatment concepts and ending with the sale of a drug candidate to international pharmaceutical companies. Kancera …See details»
Kancera - Overview, News & Similar companies | ZoomInfo.com
Who is Kancera. Kancera develops the basis for new therapeutics, starting with new treatment concepts and ending with the sale of a drug candidate to international pharmaceutical …See details»
Investor Relations - Kancera
Kancera’s board and management define and design decision paths, powers and responsibilities that are clearly defined and communicated in the organization. The Company’s Board also …See details»
Kancera AB (publ) (STO: KAN) Company Profile & Overview - Stock …
Dec 3, 2024 Kancera AB (publ) develops drugs for inflammatory diseases and cancer in Sweden and internationally. The company is developing small molecule drug candidates KAND567, …See details»
Kancera Company Profile - Office Locations, Competitors ... - Craft
Oct 29, 2024 Kancera has 5 employees across 2 locations. See insights on Kancera including office locations, competitors, revenue, financials, executives, subsidiaries and more at Craft.See details»
Kancera Company Profile 2025: Stock Performance & Earnings
Kancera AB develops drugs that counteract damage in acute and chronic inflammation. The fractalkin blockers KAND567 and KAND145 are developed to effectively counteract …See details»
First-in-Human Study with KAND567 - QPS LLC
Study to be conducted at QPS facilities in Groningen, the Netherlands. Kancera AB, a pharmaceutical development company currently focused on the treatment of cancer and …See details»
KAND567 / Kancera - LARVOL DELTA - delta.larvol.com
Kancera is planning to report study results before the end of the year 2023. This planned timeline is well in line with Kancera’s long term development plan for ovarian cancer and the objective …See details»
Kancera » Presentations
Kancera presentation at the Redeye Theme: Cardiovascular & Metabolic Diseases Event 2024. Presentation of Kancera’s Interim Report for the first quarter 2024. Presentation of Kancera’s …See details»
Numerator and Kantar Worldpanel Combine to Form New Global
2 days ago The new company's organization will be set up in compliance with local regulations. Contact Data Bob Richter Numerator 212-802-8588 [email protected] Contact ...See details»
Delving into the Latest Updates on Kancera AB with Synapse
了解Kancera AB (Kancera AB)公司的药物管线，治疗领域，技术平台，以及它的7项临床试验, 2篇新闻，疾病领域:肿瘤，免疫系统疾病，内分泌与代谢疾病，神经系统疾病，血液及淋巴系统 …See details»
Pipeline - Kancera
Kancera is evaluating opportunities for treatment of new inflammatory diseases with high medical need of more effective treatments. KAND145 in B-cell malignancies Kancera has presented …See details»